Dyne Therapeutics (DYN) to Release Quarterly Earnings on Thursday

Dyne Therapeutics (NASDAQ:DYN) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Dyne Therapeutics to post earnings of ($0.74) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $15.54 on Wednesday. The business’s fifty day moving average price is $17.76 and its 200 day moving average price is $16.92. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $25.00. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $2.22 billion, a P/E ratio of -4.25 and a beta of 1.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. grew its holdings in Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after purchasing an additional 14,727,667 shares in the last quarter. Orbis Allan Gray Ltd purchased a new position in Dyne Therapeutics in the 4th quarter valued at about $93,926,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Dyne Therapeutics during the second quarter valued at about $30,378,000. Marshall Wace LLP grew its stake in shares of Dyne Therapeutics by 572.9% during the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock valued at $38,119,000 after acquiring an additional 2,565,570 shares in the last quarter. Finally, Vestal Point Capital LP increased its position in shares of Dyne Therapeutics by 281.4% during the third quarter. Vestal Point Capital LP now owns 2,775,000 shares of the company’s stock worth $35,104,000 after acquiring an additional 2,047,500 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on DYN shares. Oppenheimer raised Dyne Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $11.00 to $40.00 in a research note on Wednesday, December 10th. Stifel Nicolaus raised their price target on shares of Dyne Therapeutics from $36.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Robert W. Baird set a $30.00 price target on shares of Dyne Therapeutics in a research report on Monday, December 8th. Royal Bank Of Canada increased their price objective on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Evercore cut their target price on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, December 15th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.41.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.